Literature DB >> 23041612

The onco-embryonic antigen ROR1 is expressed by a variety of human cancers.

Suping Zhang1, Liguang Chen, Jessica Wang-Rodriguez, Ling Zhang, Bing Cui, Wendy Frankel, Rongrong Wu, Thomas J Kipps.   

Abstract

ROR1 is an orphan-receptor tyrosine-kinase-like surface antigen that is expressed by many tissues during embryogenesis, some B-cell malignancies, and various cancer cell lines but not by virtually all normal adult tissues. Here, we report that large proportions of many different human cancers also express ROR1, particularly those cancers that have high-grade histology. Primary cancers that expressed ROR1 more commonly expressed high levels of phosphorylated AKT (p-AKT) and phosphorylated cAMP response element binding-factor (p-CREB) than similar cancers that lacked expression of ROR1. Induced expression of ROR1 could enhance basal p-AKT and p-CREB levels and could promote the growth of a cancer cell line, MEC1. Conversely, silencing ROR1 resulted in lower levels of p-AKT and p-CREB, which was associated with impaired tumor cell growth. In summary, this study found that many different human cancers express ROR1 and that ROR1 may play a functional role in promoting tumor cell growth, suggesting that this orphan-receptor tyrosine-kinase-like protein may be a potential target for therapy directed against a variety of human cancers.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23041612      PMCID: PMC3509760          DOI: 10.1016/j.ajpath.2012.08.024

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

Authors:  A Stacchini; M Aragno; A Vallario; A Alfarano; P Circosta; D Gottardi; A Faldella; G Rege-Cambrin; U Thunberg; K Nilsson; F Caligaris-Cappio
Journal:  Leuk Res       Date:  1999-02       Impact factor: 3.156

2.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

Authors:  Tomoya Yamaguchi; Kiyoshi Yanagisawa; Ryoji Sugiyama; Yasuyuki Hosono; Yukako Shimada; Chinatsu Arima; Seiichi Kato; Shuta Tomida; Motoshi Suzuki; Hirotaka Osada; Takashi Takahashi
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 3.  Activation of AKT kinases in cancer: implications for therapeutic targeting.

Authors:  Alfonso Bellacosa; C Chandra Kumar; Antonio Di Cristofano; Joseph Robert Testa
Journal:  Adv Cancer Res       Date:  2005       Impact factor: 6.242

4.  Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues.

Authors:  Xinmin Zhang; Duncan T Odom; Seung-Hoi Koo; Michael D Conkright; Gianluca Canettieri; Jennifer Best; Huaming Chen; Richard Jenner; Elizabeth Herbolsheimer; Elizabeth Jacobsen; Shilpa Kadam; Joseph R Ecker; Beverly Emerson; John B Hogenesch; Terry Unterman; Richard A Young; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

5.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.

Authors:  Sita Aggarwal; Seung-Wook Kim; Seung-Hee Ryu; Wen-Cheng Chung; Ja Seok Koo
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

7.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors.

Authors:  D J Giard; S A Aaronson; G J Todaro; P Arnstein; J H Kersey; H Dosik; W P Parks
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

8.  Expression of transcription factor CREB1 in human breast cancer and its correlation with prognosis.

Authors:  Alok Chhabra; Herman Fernando; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

9.  CREB is a critical regulator of normal hematopoiesis and leukemogenesis.

Authors:  Jerry C Cheng; Kentaro Kinjo; Dejah R Judelson; Jenny Chang; Winston S Wu; Ingrid Schmid; Deepa B Shankar; Noriyuki Kasahara; Renata Stripecke; Ravi Bhatia; Elliot M Landaw; Kathleen M Sakamoto
Journal:  Blood       Date:  2007-11-01       Impact factor: 22.113

10.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

View more
  81 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.

Authors:  Michael Y Choi; George F Widhopf; Emanuela M Ghia; Reilly L Kidwell; Md Kamrul Hasan; Jian Yu; Laura Z Rassenti; Liguang Chen; Yun Chen; Emily Pittman; Minya Pu; Karen Messer; Charles E Prussak; Januario E Castro; Catriona Jamieson; Thomas J Kipps
Journal:  Cell Stem Cell       Date:  2018-06-01       Impact factor: 24.633

3.  Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

Authors:  Julian Rydzek; Thomas Nerreter; Haiyong Peng; Sabrina Jutz; Judith Leitner; Peter Steinberger; Hermann Einsele; Christoph Rader; Michael Hudecek
Journal:  Mol Ther       Date:  2018-11-20       Impact factor: 11.454

Review 4.  Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.

Authors:  Michael Y Choi; George F Widhopf; Christina C N Wu; Bing Cui; Fitzgerald Lao; Anil Sadarangani; Joy Cavagnaro; Charles Prussak; Dennis A Carson; Catriona Jamieson; Thomas J Kipps
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-06

5.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Authors:  Ashwini Balakrishnan; Tracy Goodpaster; Julie Randolph-Habecker; Benjamin G Hoffstrom; Florencia G Jalikis; Lisa K Koch; Carolina Berger; Paula L Kosasih; Anusha Rajan; Daniel Sommermeyer; Peggy L Porter; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2016-11-16       Impact factor: 12.531

6.  Mass spectrometry-based identification of a naturally presented receptor tyrosine kinase-like orphan receptor 1-derived epitope recognized by CD8+ cytotoxic T cells.

Authors:  Falk Heidenreich; Elke Rücker-Braun; Juliane S Walz; Anne Eugster; Denise Kühn; Sevina Dietz; Annika Nelde; Antje Tunger; Rebekka Wehner; Cornelia S Link; Jan M Middeke; Friedrich Stölzel; Torsten Tonn; Stefan Stevanovic; Hans-Georg Rammensee; Ezio Bonifacio; Michael Bachmann; Matthias Zeis; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Marc Schmitz
Journal:  Haematologica       Date:  2017-08-24       Impact factor: 9.941

Review 7.  MicroRNA dysregulation and multi-targeted therapy for cancer treatment.

Authors:  Veronica Balatti; Carlo M Croce
Journal:  Adv Biol Regul       Date:  2019-10-13

8.  Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.

Authors:  Jenny Potratz; Amelie Tillmanns; Philipp Berning; Eberhard Korsching; Christiane Schaefer; Birgit Lechtape; Carolin Schleithoff; Rebekka Unland; Karl-Ludwig Schäfer; Carsten Müller-Tidow; Heribert Jürgens; Uta Dirksen
Journal:  Mol Oncol       Date:  2015-12-20       Impact factor: 6.603

9.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Authors:  Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps
Journal:  Cancer Res       Date:  2013-06-15       Impact factor: 12.701

10.  Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.

Authors:  Fan Zhang; Sirkka B Stephan; Chibawanye I Ene; Tyrel T Smith; Eric C Holland; Matthias T Stephan
Journal:  Cancer Res       Date:  2018-05-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.